| A humanized anti-CD19 monoclonal antibody being developed by Viela Bio for the treatment of NMOSD, kidney transplant desensitization, myasthenia gravis and IgG4-related disease |
| Received its first approval on 11 June 2020 in the USA |
| Approved for the treatment of NMOSD in adult patients who are AQP4-IgG seropositive |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.